Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785917 | 0.96 | DGAT1 (0.31) | DGAT1CTSK | |
| SCHEMBL136090 | 0.94 | HPGD (0.31) | DGAT1 | |
| SCHEMBL5421441 | 0.94 | HPGD (0.31) | DGAT1 | |
| SCHEMBL6504809 | 0.79 | CHRM2 (0.31) | — | |
| SCHEMBL3247299 | 0.79 | — | — | |
| SCHEMBL28868020 | 0.76 | DGAT1 (0.32) | DGAT1CTSK | |
| SCHEMBL8984073 | 0.74 | — | — | |
| SCHEMBL6320796 | 0.72 | BTK (0.31) | DGAT1 | |
| SCHEMBL14896297 | 0.71 | DGAT1 (0.32) | DGAT1CTSK | |
| SCHEMBL2064367 | 0.71 | HPGD (0.33) | DGAT1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225739-B | Preparation method of azetidine compound | 宜昌东阳光制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| EP-4025575-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-114728918-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4025568-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-114728958-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118165068-A | Difunctional compound and application thereof | 润佳(上海)医药工程有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118027041-A | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| EP-2352728-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-1797051-B1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010052255-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| CN-101031554-A | Benzoxazine and quinoxaline derivatives and uses | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | disclosed |
| EP-1797051-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006037481-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| WO-2004041795-A1 | NOVEL INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | DGAT1 1286/4885CTSK 1649/4885 |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | DGAT1 4591/4885CTSK 2961/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | DGAT1 4064/4885CTSK 2166/4885 |
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | XDH, PDHX, HAX1 | DGAT1 4768/4885CTSK 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.